Proprietary Rel-Ease™ drug delivery technology: Opportunity for sustained delivery of peptides, proteins and small molecules

Expert Opinion on Drug Delivery

Volumn 3, Issue 5, 2006, Pages 663-675

  Ye, Ming ^a   Bhat, Gajanan ^a   Johnston, Kevin A ^a   Tan, Heow ^a   Garnick, Marc ^a  

^a Praecis Pharmaceuticals Incorporated   (United States)

Author keywords

Biocompatible polymer; Depot formulation; High drug loading; Low solubility complex; Oral sustained delivery; Parenteral sustained delivery; Peptides; Proteins; Small molecules; Water soluble drugs

Indexed keywords

ABARELIX; AMITRIPTYLINE; BENZATROPINE; BOVINE SERUM ALBUMIN; CARBOXYMETHYLCELLULOSE; CEFTRIAXONE; CHITOSAN; DEXTRAN SULFATE; DEXTROMETHORPHAN; DILTIAZEM; DOXEPIN; FLUOXETINE; GROWTH HORMONE RELEASING FACTOR[1-29]; INSULIN; LEUPRORELIN; NALTREXONE; OCTREOTIDE; PEPTIDE; PHENYLTOLOXAMINE; POLYMER; PROMETHAZINE; PROPRANOLOL; PROTEIN; RIVASTIGMINE; SPARFLOXACIN; STREPTOMYCIN; TACRINE; TETRACYCLINE; TRAZODONE; UNINDEXED DRUG;

ALLERGY; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CLINICAL TRIAL; COMPLEX FORMATION; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERANCE; ENCAPSULATION; ENDOMETRIOSIS; HUMAN; HYPERTENSION; INJECTION SITE REACTION; MOLECULAR WEIGHT; PAIN; PARTICLE SIZE; PROSTATE CANCER; PULMONARY DRUG ADMINISTRATION; SUSTAINED DRUG RELEASE;

DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; LACTIC ACID; OLIGOPEPTIDES; PEPTIDES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS; PROTEINS; SOLUBILITY;

EID: 33748646547     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.5.663     Document Type: Article

References (26)

1. PATTON JS, PLATZ RM: Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Del Rev. (1992) 8:179-228.
2. SAGE BH Jr: Protein Delivery: Physical Systems. LM Sanders, RW Hendren (Eds), Plenum Press, New York, NY, USA (1997):319-341.
3. LEE VH: Non-oral routes of peptide and protein drug delivery. In: Peptide and Protein Drug Delivery. VH Lee (Ed.), Marcel Dekker, Inc., New York, NY, USA (1991):2-11.
4. WHITAKER MJ, HAO J, DAVIES OR et al: The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. J. Control. Release (2005) 101(1-3):85-92.
5. SEELY JE, BUCKEL SD, GREEN PD et al: Purification and analysis of pegylated protein pharmaceuticals presents many challenges. BioPharm International (2005) March issue.
6. 2 in a mixed solvent. Ind. Eng. Chem. Res. (2001) 40:795-800.
7. MONGIAT-ARTUS P, TEILLAC P: Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin. Pharmacother. (2004) 5(10):2171-2179.
8. PARK JM, MUHOBERAC BB et al: Effects of protein charge heterogeneity in protein-polyelectrolyte complexation. Macromolecules (1992) 25:290-295.
9. MATTISON KW, DUBIN PL et al: Complex formation between bovine serum albumin and strong polyelectrolytes: effect of polymer charge density. J Phys. Chem. B (1998) 102:3830-3836.
10. XU LC, LOGAN BE: Interaction forces measured using AFM between colloids and surfaces coated with both dextran and protein. Langmuir (2006) 22:4720-4727.
11. SATO T, MATTISON KW et al: Effect of protein aggregation on the binding of lysozyme to pyrene-labeled polyanions. Langmuir (1998) 14:5430-5437.
12. XIA J, DUBIN PL et al: Electrophoretic and quasi-elastic light scattering of soluble protein-polyelectrolyte complexes. J Phys. Chem. B (1993) 97:4528-4534.
13. CERNASEV A, GROVES MJ: Evaluation of chitosan/anionic polymers as drug delivery systems. Drug Deliv. Technol. (2006) 6(4):28-35.
14. MI FL, HER NL et al: Chitosan tablets for controlled release of theophylline: effect of polymer-drug wet or dry blending and anionic-cationic interpolymer complex. J. Appl. Polym. Sci. (1997) 66(13):2495-2505.
15. OWENS DR, BOLLI GB, ZINMAN B: Future options for insulin therapy. Current Science (2002) 83(12):1548-1555.
16. DE S, ROBINSON DH: Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres; containing bodipy. AAPS Pharm. Sci. Tech. (2004) 5(4):e53.
17. WONG SL, LAU DT, BAUGHMAN SA et al: Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. J. Clin. Pharmacol. (2004) 44(5):495-502.
18. PATTERSON DL, YUNGINGER JW et al.: Anaphylaxis induced by the carboxymethylcellulose component of injectable triamcinolone acetonide suspension Kenalog). Ann. Allerlgy Asthma Immunol. (1995) 74(2):163-166.
19. YI SHI, LUK CHIU LI: Current advances in sustained release systems for parenteral drug delivery. Expert Opin. Drug Deliv. (2005) 2(6):1039-1058.
20. CLELAND JL: Protein delivery from biodegradable microspheres. Pharm Biotechnol. (1997) 10:1-43.
21. PALAKODATY S, WALKER SE, TOWNEND G, YORK P: Particle engineering for drug delivery using supercritical fluid technologies. Life Science Today (2001) February 10 - 11.
22. CLELAND JL, JOHNSON OL, PUTNEY S et al: Recombinant human growth hormone poly(lactic-co-glycolic acid) microshere formulation development. Adv. Drug Del. Rev. (1997) 28:71-84.
23. 2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 33:433-438.
24. 2b and its therapeutic implications. Adv. Drug Del. Rev. (2002) 54:547-570.
25. VERONESE FM: Peptide and protein pegylation: a review of problems and solutions. Biomaterials (2001) 22:405-417.
26. ESPOSITO P, BARBERO L, CACCIA P et al: Pegylation of growth hormone-releasing hormone (GRF) analogues. Adv. Drug Del. Rev. (2003) 55(10):1279-1291.